Hibor, ROVI’s second-generation heparin, is the main product in terms of billing. Sales rose by 6% in 2016, totalling 79.7 million euros.
You must select the acceptance of the agreement on compliance with the established restrictions.
Access to this information is limited to certain authorized persons who are resident and physically present in jurisdictions outside the United States, Canada, Australia and Japan.
We regret that, due to regulatory restrictions, we are unable to provide you with access to this section of our website.